Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › AVLN
SILVERARC CAPITAL MANAGEMENT, LLC position in AVLN
AVALYN PHARMACEUTICALS INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 378,352 shares of AVLN (AVALYN PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$10.8M, representing 1.37% of its reported portfolio and ranking #22 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's AVLN position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in AVLN in Q2 2026 at 330,487 shares (US$10.9M). Across 2 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 378,352 shares valued at US$10.8M — an increase of 47,865 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 330.49K | $10.88M | New |
| Q3 2026 | 378.35K | $10.78M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVLN and 13F data
AVLN (AVALYN PHARMACEUTICALS INC) is a Health Care company. 113 other funds we track also report a position in AVLN — the largest reported positions include Novo Holdings A/S (US$127.8M), SR ONE CAPITAL MANAGEMENT, LP (US$108.9M), PERCEPTIVE ADVISORS LLC (US$88.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVLN
- Novo Holdings A/S 3.88M sh · $127.84M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 3.31M sh · $108.92M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.68M sh · $88.07M · Q2 2026
- MONTANOVA CAPITAL, LLC 2.50M sh · $82.40M · Q2 2026
- NVP Associates, LLC 2.27M sh · $74.68M · Q2 2026
- Catalio Capital Management, LP 1.68M sh · $55.17M · Q2 2026
- Bellevue Group AG 1.35M sh · $44.44M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 966.79K sh · $31.83M · Q2 2026
- Andera Partners 929.82K sh · $26.49M · Q3 2026
- BRAIDWELL LP 801.39K sh · $26.38M · Q2 2026
- TPG GP A, LLC 773.07K sh · $25.45M · Q2 2026
- Rock Springs Capital Management LP 662.92K sh · $21.82M · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held AVLN?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in AVLN?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 378.35K shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $10.78M, representing 1.37% of its reported portfolio and ranking #22.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling AVLN?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in AVLN.
Which other funds hold AVLN?
Other major institutional holders of AVLN include Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, among 113 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.